Partner Brent Babcock, Chair of the firm’s USPTO Trials & Post-Grant Proceedings group, was quoted in “Editas breathes sigh of relief as CRISPR ruling handed down,” an article published in MedCity News.
Partner Brent Babcock, Chair of the firm’s USPTO Trials & Post-Grant Proceedings group, was quoted in “Editas breathes sigh of relief as CRISPR ruling handed down,” an article published in MedCity News.